Antihistamines: Past answers and present questions

Current Drug Safety

Volumn 5, Issue 1, 2010, Pages 58-64

  Alberto Keller, Guillermo ^a   Di Girolamo, Guillermo ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b FAVALORO UNIVERSITY   (Argentina)

Author keywords

Antihistamines; Astemizole; HERG channel; QT interval prolongation; Terfenadine; Torsades de pointes

Indexed keywords

ACRIVASTINE; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; BROMPHENIRAMINE; CETIRIZINE; CHLORPHENIRAMINE; CYCLIZINE; DESLORATADINE; DIMENHYDRINATE; DIPHENHYDRAMINE; EBASTINE; EMEDASTINE; FEXOFENADINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYZINE; KETOTIFEN; LEVOCETIRIZINE; LORATADINE; MACROLIDE; MECLOZINE; MIZOLASTINE; OXATOMIDE; POTASSIUM CHANNEL; PROMETHAZINE; PYRROLE DERIVATIVE; QUINIDINE; RUPATADINE; TERFENADINE; UNINDEXED DRUG;

ALLERGY; ARRHYTHMOGENESIS; CARDIOTOXICITY; COMORBIDITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG INTERACTION; FOOD DRUG INTERACTION; GENETIC POLYMORPHISM; HEART ARREST; HEART ARRHYTHMIA; HEART DEATH; HEART VENTRICLE ARRHYTHMIA; HUMAN; KIDNEY; LONG QT SYNDROME; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; TORSADE DES POINTES;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; GENETIC PREDISPOSITION TO DISEASE; HISTAMINE ANTAGONISTS; HUMANS; LONG QT SYNDROME; POLYMORPHISM, GENETIC; POTASSIUM CHANNELS; RISK FACTORS; TORSADES DE POINTES;

EID: 77950633762     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610789869201     Document Type: Review

References (92)

1. Dale HH, Laidlaw PP. The physiological action of Biminazoyethylamine. J Physiol 1910; 41: 341-344
2. Yanai K, Okamura N, Tagawa M, Itoh M, Watanabe T. New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice. Clin Exp Allergy 1999; 29(3): 29-36.
3. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36: 233-252
4. Simons FE. Advances in H1-antihistamines. N Engl J Med 2004; 351: 2203-2217
5. Selzer A, Wray HW. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964; 30: 17-26.
6. Dessertenne F. La tachycardie ventriculaire a deux foyers opposes variables. Arch Mal Coeur 1966; 95: 263-272
7. Craft TM. Torsade de pointes after astemizole overdose. Br Med J 1986; 292: 660.
8. Snook J, Boothman-Burrell D, Watkins J, Colin-Jones D. Torsade de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Pract 1988; 42: 257-259
9. Davies AJ, Harinda V, McHewan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. Br Med J 1989; 298: 325.
10. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena L.R. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. J Am Med Assoc 1993; 269: 1513-1518
11. Honig P, Baranjuk JN. In: Estell F, Simon P, Eds. Adverse effects of H1-receptor antagonists in the cardiovascular system. Histamine and H1-Receptor Antagonists in Allergic Diseases. New York:Marcel Dekker Inc 1996; p. 383.
12. Markham A, Wagstaff AJ. Fexofenadine. Drugs 1998; 55: 269-274
13. Park SJ, Kim KS, Kim EJ. Blockade of HERG K(+) channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656. J Appl Toxicol 2007; 28: 104-111
14. Shin WH, Kim KS, Kim EJ. Electrophysiological effects of brompheniramine on cardiac ion channels and action potential. Pharmacol Res 2006; 54: 414-420
15. Taglialatela M, Timmerman H, Annunziato L. Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends Pharmacol Sci 2000; 21: 52-56
16. Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996; 385: 77-80.
17. Taglialatela M, Pannaccione A, Castaldo P, et al. The molecular basis for the lack of HERG K+ channels blockrelated cardiotoxicity by the H1 receptor blocker cetirizine as compared to other secondgeneration antihistamines. Mol Pharmacol 1998; 54: 113-121
18. Zhou Z, Vorperian VR, Gong Q, Zhang S, January CT. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J CardioVasc Electrophysiol 1999; 10: 836-843
19. Ko CM, Ducic I, Fan J, Shuba YM, Morad M. Suppression of mammalian K+ channel family by ebastine. J Pharmacol Exp Ther 1997; 281: 233-244
20. Roy ML, Dumaine R, Brown A.M. HERG, a primary human ventricular target of the non sedating antihistamine terfenadine. Circulation 1996; 94: 817-823
21. Crumb WJ. Loratadine blockade of K+ channels in human heart: Comparison with terfenadine under physiological conditions. J Pharmacol Exp Ther 2000; 292: 261-264
22. Kreutner W, Hey JA, Chiu P, Barnett A. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung 2000; 50: 441-448
23. Taglialatela M, Pannaccione A, Castaldo P, Giorgio G, Annunziato L. Inhibition of HERG1 K+ channels by the novel secondgeneration antihistamine mizolastine. Br J Pharmacol 2000; 131: 1081-1088
24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs (E14 Guideline). Available at: http://www.ich.org/
25. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (S7B Guideline). Available at: http://www.ich.org/
26. Estelle F, Simons R, Simons KJ. Pharmacokinetic optimization of histamine H1 receptor antagonist therapy. Clin Pharmacokinet 1991; 21: 372-393
27. Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990; 96: 195-215.
28. Borchert B, Lawrenz T, Stellbrink C. Long and short QT syndrome. Herzschrittmacherther Elektrophysiol 2006; 17: 205-210
29. Priori SG, Rivolta I, Napolitano C. In: Zipes DP, Jalife J, Eds. Genetics of long QT, brugada and other channelopathies. In Cardiac Electrophysiology. From Cell to Bedside, 4th ed. Philadelphia, PA: WB Saunders, Co 2004; pp. 462-470
30. Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes. Mechanisms and management. Drugs 1994; 47: 51-65.
31. Antzelevitch C, Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm 2005; 2 (Suppl 2): S9-S15.
32. Vorperian VR, Zhou Z, Mohammad S, Hoon TJ, Studenik C, January CT. Torsade de pointes with an antihistamine metabolite: Potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 1996; 28: 1556-1561
33. Moller C, Andlin-Sobocki P, Blychert LO. Pharmacokinetics of astemizole in children. Rhinology 1992; 30 (Suppl13): 21-25
34. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarisation on the electrocardiogram. Clin Pharmacol Ther 1996; 59: 383-388
35. Clifford CP, Adams DA, Murray S, et al. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 1997; 52: 311-315
36. Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P-450 3A (4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993; 21: 403-409
37. Ling KHJ, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK. Metabolism of terfenadine associated with CYP3A (4) activity in human hepatic microsomes. Drug Metab Dispos 1995; 23: 631-636
38. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by erythromycin breath test. Drug Metab Dispos 1994; 22: 947-955
39. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Res 1997; 27: 161-170
40. Herbert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Res 1997; 27: 201-214
41. Schuetz EG, Beck WT, Schuetz JD. Modulation and substrates of P-glycoprotein and cytochrome P4503A coordinately upregulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49: 311-318
42. Rabbaa L, Pautrey S, Colas-Linhart N, Carbon C, Farinotti R. Intestinal elimination of ofloxacin enantiomers in the rat: Evidence of a carrier-mediated process. Antimicrob Agents Chemother 1996;40: 2126-2130
43. Chan TYK. Terfenadine-induced torsade de pointes: risk factors and mechanisms. J Pharm Technol 1997; 13: 127-132
44. Kamisako T, Adachi Y, Nakagawa H, Yamamoto T. Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma. Intern Med 1995; 34: 92-95
45. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997; 61: 410-415
46. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena L.R. Torsades de pointes occurring in association with terfenadine use. J Am Med Assoc 1990; 264: 2788-2790
47. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450-482
48. Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985; 10: 63-79.
49. Watkins VS, Polk RE, Stotka JL, Labrada L, Dion P. Drug interactions of macrolides: emphasis on dirithromycin. Ann Pharmacother 1997; 31: 349-356
50. Honig PK, Wortham DC, Zamani K, et al. Terfenadineketoconazole interaction: pharmacokinetic and electrocardiographic consequences. J Am Med Assoc 1993; 269: 1513-1518
51. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993; 45: 191-193
52. Honig PK, Wortham DC, Hull R, et al. Itraconazole affects singledose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993; 33: 1201-1206
53. Lefebvre RA, Van-Peer A, Woestenborghs R. Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. Br J Clin Pharmacol 1997; 43: 319-322
54. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena L.R. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52: 231-238
55. Honig PK, Wortham DC, Zamani K, Cantilena L.R. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994; 7: 148-156
56. De-Wildt SN, Van-den-Anker JN, Romkes JH, et al. Loss of consciousness due to simultaneous use of terfenadine and itraconazole. Ned Tijdschr Geneeskd 1997; 141: 1752-1754
57. Honig PK, Wortham DC, Zamani K, et al. Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and elctrocardiographic effects of terfenadine. Eur J Clin Pharmacol 1993; 45: 41-46
58. Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R. Azithromycin and terfenadine: Lack of drug interaction. Clin Pharmacol Ther 1995; 58: 310-315
59. Renwick AG, Le Vie J, Challenor VF, et al. Factors affecting the pharmacokinetics of nifedipine. Eur J Clin Pharmacol 1987; 32: 351-355
60. Awni WM, Cavanaugh JH, Leese P, et al. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. Eur J Clin Pharmacol 1997; 52: 49-54.
61. Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996; 57 (Suppl 2): 31-38
62. Nemeroft CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome p450 system. Am J Psychiatry 1996; 153: 311-320
63. Li AP, Jurima-Romet M. Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: Evaluation of model drugs terfenadine and rifampcin. Cell Biol Toxicol 1997; 13: 365-374
64. Von-Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996; 16: 104-112
65. Von-Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995; 29 (Suppl 1): 33-44.
66. Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver: In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994; 22: 849-857
67. Jurima-Romet M, Huang HS, BeckDJ, Li AP. Evaluation of drug interactions in intact hepatocytes: inhibitors of terfenadine metabolism. Toxicol Vitro 1996; 10: 655-663
68. de Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. Grapefruit juice-drug interactions: grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci 2007; 96(10): 2808-2817
69. Yap YG, Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation. Br Med J 2000; 320: 1158-1159
70. Lessard E, Yessine MA, Hamelin BA, et al. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 2001; 21: 175-184
71. Taglialatela M. In: Pugsley MK, Ed. Heterologous expression systems and screening technologies. Cardiac Drug Development Guide. Totowa, NJ: Humana Press 2003; pp. 227-244
72. Lacerda AE, Roy ML, Lewis EW, Rampe D. Interaction of the nonsedating antihistamine loratadine with a Kv1.5 type potassium channel cloned from human heart. Mol Pharmacol 1997; 52: 314-322
73. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 2006; 316: 1098-1106
74. Lindquist M, Edwards IR. Risk of non-sedating antihistamines. Lancet 1997; 349: 1322.
75. Kosoglou T, Salfi M, Lim JM, Batra VK, Cayen MN, Affrime MB. Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine. Br J Clin Pharmacol 2000; 50 : 581-589
76. Abernethy DR, Barbey JT, Franc J, et al. Loratadine and terfenadine interaction with nefazodone, both antihistamines are associated with QTc prolongation. Clin Pharmacol Ther 2001; 69: 96-103.
77. Bianchi L, Wible B, Arcangeli A, et al. HERG encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells. Cancer Res 1998; 58: 815-822
78. Khalifa M, Drolet B, Daleau P, et al. Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. J Pharmacol Exp Ther 1999; 288: 858-865
79. Pratt CM, Hertz RP, Ellis BE, Crowell SP, Louv W, Moyé L. Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-thecounter antihistamines, ibuprofen and clemastine. Am J Cardiol 1994; 73: 346-352
80. Ridley JM, Milnes JT, Hancox JC, Witchel HJ. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel. J Mol Cell Cardiol 2006; 40: 107-118
81. Ki I, Inui A, Ito T. Effects of histamine H1 receptor antagonists on action potentials in guinea-pig isolated papillary muscles. Arch Int Pharmacodyn Ther 1996; 331: 59-73.
82. Wang WX, Ebert SN, Liu XK, Chen YW, Drici MD, Woosley RL. Conventional antihistamines slow cardiac repolarization in isolated perfused (Langendorff) feline hearts. J Cardiovasc Pharmacol 1998; 32: 123-128
83. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000; 47: 219-233
84. Roden DM. Genetic polymorphisms, drugs, and proarrhythmia. J Interven Cardiol Electrophysiol 2003; 9: 131-135
85. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes Circulation 2002; 105: 1943-1948
86. Moule SK, Denton RM. The activation of p38 MAPK by the betaadrenergic agonist isoproterenol in rat epididymal fat cells. FEBS Lett 1998; 439: 287-290
87. Priori SG, Napolitano C. Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes. Cardiovasc Drugs Ther 2002; 16: 89-92.
88. Fitzgerald PT, Ackerman MJ. Drug-induced torsades de pointes: The evolving role of pharmacogenetics. Heart Rhythm 2005; 2 (Suppl 2): S30-7.
89. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs J Am Med Assoc 1993; 270: 2590-2597
90. Anantharam A, Markowitz S, Abbott GW. Pharmacogenetic considerations in diseases of cardiac ion channels. J Pharmacol Exp Ther 2003; 307: 831-838
91. Kubota T, Horie M, Takao M, et al. Evidence for a single nucleotide polymorphism in the KCNQ1 potassium channel that underlies susceptibility to life-threatening arrhythmias. J Cardiovasc Electrophysiol 2001; 12: 1223-1229
92. Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002; 297: 1333-1336